On June 23, 2025, Opus Genetics, Inc. announced it was awarded up to $2 million in non-dilutive funding from the Retinal Degeneration Fund (RD Fund), the venture philanthropy arm of the Foundation Fighting Blindness. This funding is intended to support the advancement of Opus’ OPGx-MERTK program.
The OPGx-MERTK program aims to develop gene therapies for retinitis pigmentosa caused by pathogenic variants in the MERTK gene, a condition with no currently approved therapies. This strategic funding will enable the program to move towards Investigational New Drug (IND) enabling studies.
With the addition of this funding, Opus Genetics believes its cash on hand will now be sufficient to fund operations into the second half of 2026. This non-dilutive capital is crucial for mitigating shareholder dilution while advancing its early-stage gene therapy assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.